Kuros Biosciences announces changes in the Board of Directors

Company Overview - Kuros Biosciences is a leader in next-generation bone healing technologies, with a mission to discover, develop, and deliver innovative biologic technologies [2][7] - The company is listed on the SIX Swiss Exchange and has locations in the United States, Switzerland, and the Netherlands [7] Board of Directors Changes - Albert Arp has resigned from the Board of Directors for personal and professional reasons, effective immediately [2] - Oliver Walker has been appointed as Chair of the Audit and Risk Committee [2] - Kimberley Elting has been appointed as a member of the Audit and Risk Committee and as Chair of the Compensation and Nomination Committee [2] Product Information - Kuros's first commercial product, MagnetOs, is an advanced bone graft that has been used across four continents [7] - In a Level I human clinical study, MagnetOs achieved a fusion rate of 79%, nearly double that of autograft at 47% in posterolateral fusions [5] - Among active smokers, the fusion difference was even more pronounced, although specific data for this subgroup was not statistically analyzed [5][9] - MagnetOs utilizes NeedleGrip technology to stimulate bone growth without added cells or growth factors, and it is FDA cleared for use throughout the spine [5]